929b Larazotide Acetate, a First In-Class, Novel Tight Junction Regulator, Meets Primary Endpoint and Significantly Reduces Signs and Symptoms of Celiac Disease in Patients on a Gluten-Free Diet: Results of a Multicenter, Randomized, Placebo Controlled Trial
2014; Elsevier BV; Volume: 146; Issue: 5 Linguagem: Inglês
10.1016/s0016-5085(14)60566-7
ISSN1528-0012
AutoresChao Wang, Henrik Rasmussen, Wendy Perrow, Ciarán P. Kelly, Daniel A. Leffler, Peter Green, Richard N. Fedorak, Anthony J. DiMarino, Přemysl Berčík, Joseph A. Murray, Natalie M. Bachir,
Tópico(s)Celiac Disease Research and Management
ResumoLarazotide Acetate, a First In-Class, Novel Tight Junction Regulator, Meets Primary Endpoint and Significantly Reduces Signs and Symptoms of Celiac Disease in Patients on a Gluten-Free Diet: Results of a Multicenter, Randomized, Placebo Controlled Trial Chao Wang, Henrik Rasmussen, Wendy Perrow, Ciaran P. Kelly, Daniel Le7ffler, Peter Green, Richard N. Fedorak, Anthony J. DiMarino, Premysl Bercik, Joseph A. Murray, Natalie M. Bachir
Referência(s)